| Literature DB >> 35324844 |
Pamela Martínez-Orellana1, Noemí González1, Antonella Baldassarre2, Alejandra Álvarez-Fernández1, Laura Ordeix1, Paola Paradies2, Manuel Soto3, Laia Solano-Gallego1.
Abstract
The effect of Leishmania infantum soluble antigen (LSA) and recombinant Kinetoplastid Membrane Protein 11 (rKMP11) on the induction of ex vivo specific IFN-γ (n = 69) and antibody responses (n = 108) was determined in dogs. All dogs were tested for serological response to both antigens and divided into Group 1: healthy (Asturias, Spain, n = 26), Group 2: sick (n = 46), Group 3: healthy Ibizan hounds (Mallorca, Spain, n = 22) and Group 4: healthy (Bari, Italy, n = 14). Antibody levels were higher for LSA when compared to rKMP11 (p = 0.001). Ibizan hounds were all seronegative to rKMP11 and 18% were low seropositive to LSA. Sick dogs presented higher antibody response to both antigens compared to the rest of the groups (p < 0.0001). All groups showed higher IFN-γ levels after LSA compared to rKMP11 responses (p < 0.05). The highest response to LSA was found in Ibizan hounds (p < 0.05). IFN-γ to LSA and rKMP11 stimulation was observed in 34% and in 2.8% of the sick dogs, respectively. Here, we demonstrated that anti-rKMP11 antibodies are mainly present in dogs with moderate to severe disease. Furthermore, cellular immune response measured by specific ex vivo IFN-γ production was more intense to LSA than stimulated to rKMP11.Entities:
Keywords: cell-mediated immunity; diagnosis; dog; leishmaniosis; serology
Year: 2022 PMID: 35324844 PMCID: PMC8954708 DOI: 10.3390/vetsci9030116
Source DB: PubMed Journal: Vet Sci ISSN: 2306-7381
Figure 1Specific (a) L infantum and (b) rKMP11 antibodies levels in apparently healthy non-infected dogs from a low endemicity area, Asturias, Spain (Group 1), sick dogs from Catalonia, Spain (Group 2) apparently healthy Ibizan hounds from a high endemicity area, Mallorca, Spain (Group 3) and apparently healthy dogs from a high endemicity area, Bari, Italy (Group 4).
Figure 2Specific (a) L. infantum and (b) rKMP11 antibody levels in sick dogs (Group 2) classified based on LeishVet clinical staging.
Positive results to specific L. infantum and rKMP11 antibodies in apparently healthy non-infected dogs from Asturias (Spain), a low endemicity area (Group 1), sick dogs from Catalonia (Spain) (Group 2), apparently healthy Ibizan hound dogs from the high endemicity area of Mallorca (Spain) (Group 3), and apparently healthy dogs from the high endemicity area of Bari, Italy (Group 4).
| Total Dogs ( | Positive Antibody Response | |
|---|---|---|
| rKMP11 | ||
| Group 1 ( | 0 (0) | 0 (0) |
| Group 2 ( | ||
| Stage I ( | 1 (3.1) | 0 (0) |
| Group 3 ( | 4 (18.1) | 0 (0) |
| Group 4 ( | 0 (0) | 0 (0) |
| Total | 46 (42.5) | 26 (24) |
N = number of dogs by group positive to the test, % = percentage of dogs by group positive to the test.
Figure 3Specific ex vivo IFN-γ concentration after L. infantum, rKMP11 and ConA stimulation in apparently healthy non-infected dogs from a low endemicity area, Asturias, Spain (Group 1), sick dogs from Catalonia, Spain (Group 2), apparently healthy Ibizan hounds from a high endemicity area, Mallorca, Spain (Group 3) and apparently healthy dogs from a high endemicity area, Bari, Italy (Group 4).
Positive results to specific ex vivo IFN-γ response to L. infantum and rKMP11 in apparently healthy non-infected dog from Asturias, Spain, a low endemicity area (Group 1), sick dogs from Catalonia (Spain) (Group 2), apparently healthy Ibizan hound dogs from the high endemicity area of Mallorca (Spain) (Group 3) and apparently healthy dogs from the high endemicity area of Bari (Italy) (Group 4).
| Total Dogs ( | IFNγ Response | |
|---|---|---|
| LSA | rKMP11 | |
| Group 1 ( | 0 (0) | 0 (0) |
| Group 2 ( | ||
| Stage I ( | 2 (13.3) | 2 (13.3) |
| Group 3 (n = 16) | 12 (75) | 0 (0) |
| Group 4 (n = 13) | 7 (53.8) | 0 (0) |
| Total | 24 (34.7) | 2 (2.8) |
N = number of dogs by group positive to the test, % = percentage of dogs by group positive to the test, LSA = Leishmania soluble antigen.